CD8A and neoplasm: Similarly, targeting PD-1, PD-L1, and CTLA-4 with monoclonal antibodies has been shown to reverse CD8+ T cell exhaustion and enhance lytic capabilities [48,49,50] as well as promote tumor shrinkage and survival for many cancer patients [51,52,53].